

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Stelara under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹⁻¹³

- Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for phototherapy or systemic therapy (Reference the Biological Response Modifiers (BRMs) in the Treatment of Plaque Psoriasis NJ Protocol)
- Active psoriatic arthritis (PsA) in patients 6 years and older
- Moderately to severely active Crohn's disease (CD) in adults
- Moderately to severely active ulcerative colitis (UC) in adults

Compendial Uses^{27,29}


Immune checkpoint inhibitor-related toxicity

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

<u>Preferred:</u> Yesintek (ustekinumab-kfce)

Non-preferred: Stelara (ustekinumab) Imuldosa (ustekinumab-srlf) Otulfi (ustekinumab-aauz) Pyzchiva (ustekinumab-atwe) Selarsdi (ustekinumab-aekn) Steqeyma (ustekinumab-stba) Wezlana (ustekinumab-auub) ustekinumab (unbranded Stelara) ustekinumab-aauz (unbranded Otulfi) ustekinumab-aekn (unbranded Selarsdi)



ustekinumab-stba (unbranded Steqeyma) ustekinumab-ttwe (unbranded Pyzchiva)

Policy/Guideline:

Documentation for all indications:

The patient is unable to take Yesintek (ustekinumab-kfce), where indicated, for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Psoriatic arthritis (PsA)

Initial requests

Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

Continuation requests

Chart notes or medical record documentation supporting positive clinical response.

Crohn's disease (CD) and ulcerative colitis (UC)

Continuation requests: Chart notes or medical record documentation supporting positive clinical response to therapy or remission.


Immune checkpoint inhibitor-related toxicity

Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

Prescriber Specialties

This medication must be prescribed by or in consultation with one of the following:

- Psoriatic arthritis: rheumatologist or dermatologist
- Crohn's disease and ulcerative colitis: gastroenterologist
- Immune checkpoint inhibitor-related toxicity: gastroenterologist, hematologist, or oncologist



Coverage Criteria

Psoriatic arthritis (PsA)^{1-13,23,28}

Authorization of 12 months may be granted for members 6 years of age or older who have previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.

Authorization of 12 months may be granted for members 6 years of age or older for treatment of active psoriatic arthritis when either of the following criteria is met:

- Member has mild to moderate disease and meets one of the following criteria:
 - Member has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration.
 - Member has an intolerance or contraindication to methotrexate or leflunomide (see Appendix), or another conventional synthetic drug (e.g., sulfasalazine).
 - Member has enthesitis.
- Member has severe disease.

Crohn's disease (CD)1-13,17,18,26

Authorization of 12 months may be granted for treatment of moderately to severely active Crohn's disease.

Ulcerative colitis (UC)^{1-13,17,21,22}

Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.


Immune checkpoint inhibitor-related toxicity^{27,29}

Authorization of 6 months may be granted for treatment of immune checkpoint inhibitorrelated diarrhea or colitis when the member has experienced an inadequate response, intolerance, or has a contraindication to infliximab or vedolizumab.

Continuation of Therapy

Psoriatic arthritis (PsA)^{1-16,23,26,28}

Authorization of 12 months may be granted for all members 6 years of age or older (including new members) who are using the requested medication for psoriatic arthritis and who achieve or maintain a positive clinical response as evidenced by low disease activity or



improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

- Number of swollen joints
- Number of tender joints
- Dactylitis
- Enthesitis
- Skin and/or nail involvement
- Functional status
- C-reactive protein (CRP)

Crohn's Disease (CD)1-13,17,18,26

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn's disease and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn's disease and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

- Abdominal pain or tenderness
- Diarrhea
- Body weight
- Abdominal mass
- Hematocrit
- Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
- Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score)

Ulcerative colitis^{1-13,17,21,22}

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:



Coverage Policy/Guideline

Name: Stelara and Biosimilars		ilars	Page:	5 of 9	
Effective Date: 6/20/2025			Last Review Date:	5/2025	
Applies to:	□Illinois	□Florida	□Florida Kids		
	⊠New Jersey	□Maryland	□Michigan		
	🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD		

- Stool frequency
- Rectal bleeding
- Urgency of defecation
- C-reactive protein (CRP)
- Fecal calprotectin (FC)
- Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
- Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo score)

Immune checkpoint inhibitor-related toxicity

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the Coverage Criteria.

Other^{1-13,20}

For all indications: Member has had a documented negative tuberculosis (TB) test (which can include a tuberculosis skin test [TST] or an interferon-release assay [IGRA]) within 12 months of initiating therapy for persons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB.

If the screening testing for TB is positive, there must be further testing to confirm there is no active disease (e.g., chest x-ray). Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

For all indications: Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

Dosage And Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Appendix

Examples of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, Cyclosporine, Acitretin, or Leflunomide²⁵

Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease



Coverage Policy/Guideline

coverage i enegr daladarie					
Name:	Name: Stelara and Biosimilars		Page:	6 of 9	
Effective Date: 6/20/2025			Last Review Date:	5/2025	
Applies to:	□Illinois	□Florida	🗆 Florida Kids		
	⊠New Jersey	□Maryland	□Michigan		
	🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD		

- Drug interaction
- Risk of treatment-related toxicity
- Pregnancy or currently planning pregnancy
- Breastfeeding
- Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension)
- Hypersensitivity
- History of intolerance or adverse event

Approval Duration and Quantity Restrictions:

Approval:

Initial Approval:

- 6 months for Immune checkpoint inhibitor-related toxicity
- 12 months for all other indications

Renewal Approval:

- 6 months for Immune checkpoint inhibitor-related toxicity
- 12 months for all other indications

Quantity Level Limit:

- Stelara (ustekinumab) 130 mg/26 mL singledose vial:
 - 4 vials (1 dose)
- Stelara (ustekinumab) subcutaneous injection 45 mg/0.5 mL single-dose vial/prefilled syringe
 - o 1 vial/syringe per 84 days
 - Exception limit: 2 vials/syringes per 28 days
- Stelara (ustekinumab) subcutaneous injection 90 mg/mL prefilled syringe
 - 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days
- Imuldosa (ustekinumab-srlf) 130 mg/26 mL single-dose vial
 - o 4 vials (1 dose)
- Imuldosa (ustekinumab-srlf) subcutaneous injection 45 mg/0.5 mL prefilled syringe
 - 1 syringe per 84 days
 - Exception limit: 2 syringes per 28 days
- Imuldosa (ustekinumab-srlf) subcutaneous injection 90 mg/mL prefilled syringe
 - \circ 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days



Coverage Policy/Guideline

Name: Stelara and Biosimilars Page: 7 of 9					
Stelara and Biosimilars		Page:	7 of 9		
Effective Date:6/20/2025Last Review Date:5/2025					
□Illinois	□Florida	🗆 Florida Kids			
⊠New Jersey	□Maryland	□Michigan			
🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD			
	e: 6/20/2025 ∃Illinois ⊠New Jersey	□Illinois □Florida ⊠New Jersey □Maryland	e: 6/20/2025 Last Review Date: Illinois IFlorida IFlorida New Jersey Maryland Michiga		

- Otulfi (ustekinumab-aauz) 130 mg/26 mL single-dose vial
 - \circ 4 vials (1 dose)
- Otulfi (ustekinumab-aauz) subcutaneous injection 45 mg/0.5 mL prefilled syringe
 - 1 syringe per 84 days
 - Exception limit: 2 syringes per 28 days
- Otulfi (ustekinumab-aauz) subcutaneous injection 90 mg/mL prefilled syringe
 - 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days
- Pyzchiva (ustekinumab-ttwe) 130 mg/26 mL single-dose vial
 - \circ 4 vials (1 dose)
- Pyzchiva (ustekinumab-ttwe) subcutaneous injection 45 mg/0.5 mL single-dose vial/prefilled syringe
 - 1 vial/syringe per 84 days
 - Exception limit: 2 vials/syringes per 28 Days
- Pyzchiva (ustekinumab-ttwe) subcutaneous injection 90 mg/mL prefilled syringe
 - 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days
- Selarsdi (ustekinumab-aekn) 130 mg/26 mL single-dose vial
 - \circ 4 vials (1 dose)
- Selarsdi (ustekinumab-aekn) subcutaneous injection 45 mg/0.5 mL prefilled syringe
 - o 1 syringe per 84 days
 - Exception limit: 2 syringes per 28 days
- Selarsdi (ustekinumab-aekn) subcutaneous injection 90 mg/mL prefilled syringe
 - \circ 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days
- Steqeyma (ustekinumab-stba) 130 mg/26 mL single-dose vial
 - 4 vials (1 dose)
- Steqeyma (ustekinumab-stba) subcutaneous injection 45 mg/0.5 mL prefilled syringe
 - 1 syringe per 84 days
 - Exception limit: 2 syringes per 28 days
- Steqeyma (ustekinumab-stba) subcutaneous injection 90 mg/mL prefilled syringe
 - o 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days
- Wezlana (ustekinumab-auub) 130 mg/26 mL single-dose vial
 - o 4 vials (1 dose)




Coverage Policy/Guideline

ame: Stelara and Biosimilars		Page:	8 of 9		
ate: 6/20/2025		Last Review Date:	5/2025		
□Illinois	□Florida	🗆 Florida Kids			
⊠New Jersey	□Maryland	□Michigan			
🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD			
	Stelara and Biosim ate: 6/20/2025 □Illinois ⊠New Jersey	Stelara and Biosimilars ate: 6/20/2025 Illinois IFlorida New Jersey Maryland	Stelara and BiosimilarsPage:ate:6/20/2025Last Review Date:IllinoisIllinoisFloridaNew JerseyMarylandMichiga		

- Wezlana (ustekinumab-auub) subcutaneous injection 45 mg/0.5 mL single-dose vial/prefilled syringe/ConfiPen autoinjector
 - o 1 vial/syringe/autoinjector per 84 days
 - o Exception limit: 2 vials/syringes/autoinjectors per 28 days
- Wezlana (ustekinumab-auub) subcutaneous injection 90 mg/mL prefilled syringe/ConfiPen autoinjector
 - 1 syringe/autoinjector per 56 days
 - Exception limit: 2 syringes/autoinjectors per 28 days
- Yesintek (ustekinumab-kfce) 130 mg/26 mL single-dose vial
 - 4 vials (1 dose)
- Yesintek (ustekinumab-kfce) subcutaneous injection 45 mg/0.5 mL single-dose vial/prefilled syringe
 - 1 vial/syringe per 84 days
 - Exception limit: 2 vials/syringes per 28 days
- Yesintek (ustekinumab-kfce) subcutaneous injection 90 mg/mL prefilled syringe
 - 1 syringe per 56 days
 - Exception limit: 2 syringes per 28 days

References:

- 1. Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc.; November 2024.
- 2. Imuldosa [package insert]. Raleigh, NC: Accord BioPharma Inc.; October 2024.
- 3. Otulfi [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024.
- 4. Pyzchiva [package insert]. Princeton, NJ: Sandoz Inc.; December 2024.
- 5. Selarsdi [package insert]. Leesburg, VA: Alvotech USA Inc.; October 2024.
- 6. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.
- 7. ustekinumab [package insert]. Horsham, PA: Janssen Biotech, Inc.; April 2025.
- 8. ustekinumab-aauz [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; April 2025.
- 9. ustekinumab-aekn [package insert]. Leesburg, VA: Alvotech USA Inc.; October 2024.
- 10. ustekinumab-stba [package insert]. Jersey City, NJ: Celltrion USA, Inc.; April 2025.
- 11. ustekinumab-ttwe [package insert]. Grand Cayman, Cayman Islands: Quallent Pharmaceuticals Health LLC; March 2025.
- 12. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc.; December 2024.
- 13. Yesintek [package insert]. Cambridge, MA: Biocon Biologics Inc.; November 2024.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.



			- 3	
Effective Date: 6/20/2025			Last Review Date:	5/2025
Applies to:	□Illinois	□Florida	🗆 Florida Kids	
	⊠New Jersey	□Maryland	□Michigan	
	🗆 Pennsylvania Kids	□Virginia	□Kentucky PRMD	

Name:

- 15. Gossec L, Baraliakos X, Kerschbaumer A, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712.
- 16. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14-ii17.
- 17. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2-S25.
- 18. Lichtenstein GR, Loftus Jr EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517.
- 19. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
- 20. Testing for TB Infection. Centers for Disease Control and Prevention. Retrieved on January 21, 2025 from: https://www.cdc.gov/tb/testing/index.html.
- 21. Rubin DT, Ananthakrishnan AN, et al. 2019 ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413.
- 22. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158:1450.
- 23. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32. doi:10.1002/art.40726.
- 24. Menter A, Cordero KM, Davis DM, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201.
- 25. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6): 1445-86.
- 26. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021; 160: 2496-2508.
- 27. The NCCN Drugs & Biologics Compendium[®] © 2025 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed January 14, 2025.
- 28. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479.
- 29. NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®). Management of Immunotherapy-related Toxicities. Version 1.2025. Available at: www.nccn.org. Accessed January 21, 2025.